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Abstract                   
Purpose.  The aim of this paper is to highlight the contributions that complementary 
efficacy, effectiveness, and cost-effectiveness studies can make to assessing the outcomes 
of assistive technology interventions for enhancing mobility.                                     
Method.  The terms, “assistive technology outcomes research” and “assistive technology 
interventions,” are defined.  Several bases are examined for the shortage of outcomes 
research pertaining to mobility-related assistive technology interventions.  Three 
presuppositions are described for the research strategy of interlocking studies being 
recommended.  They are 1) assigning priority to evaluating both recently developed 
assistive technologies and ones that have long available, acknowledging the complexity 
of assistive technology as an intervention, and appreciating the trade-offs necessary for 
strengthening studies’ internal and external validity.  Some key study preparations are 
considered, including treatment theory, treatment specification, and the selection of 
outcome domains and measures.  The essential features of efficacy, effectiveness, and 
cost-effectiveness studies are outlined, and their interdependence is stressed. 
Results and Conclusions.  To assess the outcomes of assistive technology interventions 
for mobility in ways that are both methodologically sound and relevant to stakeholder 
needs, a research strategy is required involving mutually reinforcing efficacy, 
effectiveness, and cost-effectiveness studies.  Collaborative arrangements and funding 







 Assistive technology (AT) outcomes research seeks to identify the changes 
produced by AT interventions in the lives of users and their environments [1].  Achieving 
that goal depends to a significant extent on conducting studies that 1) employ technically 
sound measures of outcomes that are relevant to stakeholders, 2) use study designs 
resulting in persuasive evidence that AT interventions are actually responsible for the 
ostensible outcomes, and 3) communicate the resulting information in ways that 
stakeholders can understand and use.  The present focus is on the second of those 
requirements, i.e., generating convincing evidence that AT interventions indeed produce 
the outcomes attributed to them.   
This paper highlights some of the limitations of available AT outcomes research, 
discusses some research designs for strengthening both its quality and relevance, and 
recommends several steps for promoting needed collaboration and funding.  Apropos the 
ensemble of papers to which this one belongs, illustrations of AT interventions are drawn 
from the mobility domain.  However, the principal points apply to AT interventions in 
many domains. 
 An AT intervention is described by two vital pieces of information, one pertaining 
to assistive technology devices (ATDs) themselves, the other to the services that result in 
users acquiring and using them [1].  Information about ATDs may pertain to their 
physical description, the functional performance they are intended to facilitate, and their 
particular features that enhance that performance.  Information about the services 
surrounding their provision may concern how a candidate user is assessed (e.g. regarding 
the individual’s functional needs), the expertise being drawn on to select a particular 
 3
ATD, the manner in which it may be customised to meet the user’s requirements, the 
training that may be provided in its use, and the provisions being made for maintaining it 
in operating condition [2].  These distinctions underscore the theoretical point that the 
findings of an AT outcomes study may fall short of expectations because the device 
underperformed, the services were insufficient, or because both factors were in play [1].      
Most AT interventions of relevance to mobility have not been submitted to 
rigorous evaluative research [3,4,5].  Much of the evidence that does exist is vulnerable 
to substantial methodological criticism.  For example, many published studies of mobility 
ATDs have used outcome measures that are relatively underdeveloped from a 
psychometric viewpoint [6], and as discussed subsequently, most have not dealt well with 
methodologic issues involving treatment theory, treatment specification, and treatment 
fidelity. 
 Several reasons exist for the paucity of relevant outcomes research related to 
mobility.  Some ATDs such as canes, crutches, and walkers, have a lengthy history of 
widespread usage.  Little or no doubt exists that they benefit many users, notwithstanding 
uncertainty about the particular types of devices that enhance specific forms of mobility 
for users with particular impairments.  Outcome studies tend to be costly, and the 
necessary funding is a struggle to obtain.  Unlike some therapeutic or diagnostic 
technologies, evidence attesting to the benefits of most types of ATDs is not required by 
federal regulatory agencies in the USA.  Many relatively new mobility devices enjoy at 
least limited market success without having any research-based evidence that confirms 
their value.  The hopeful implication seems to be that sales alone are evidence of devices’ 
importance to users.  Finally, outcomes research may be unattractive to some developers 
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or manufacturers who fear that the findings may not support their claims for the benefits 
conferred on users. 
The tenants of evidence-based practices (EBPs) have been championed in the 
literature of numerous health professions, among them being Occupational Therapy [7] 
and Physical Therapy [8], professions with which many AT providers are affiliated.  
According to a definition by the Institute of Medicine [9] that is derived from one by 
Sackett et al. [10], EBPs are based on “…the integration of best research evidence with 
clinical expertise and patient values".  Inevitably, AT providers who are proponents of 
EBPs must deal with the frustration of wanting to support their clinical decisions with 
quality research evidence, but finding precious little of it available.   
 Third-party payers for health services have increasingly utilised evidence-based 
approaches to justify decisions about the interventions for which they will authorize 
payment.  The processes established by Medicare, a U.S. public sector payer, are 
especially noteworthy for their sophistication and public accessibility [11].  Medicare, the 
leading third-party payer for mobility-related ATDs in the U.S.A. [12], is a federally 
administered hospital and medical-care insurance programme for people age 65 or older 
and for some people with disabilities.           
 The approach that Medicare took to reevaluating its guidelines for paying for 
mobility ATDs is particularly instructive [13].  A well-documented process was used in 
which the review and quality assessment of available outcomes research were central.  A 
working group appointed by the Centers for Medicare and Medicaid Services (CMS), the 
federal agency responsible for administering Medicare, spearheaded the effort.  Members 
of the group included federal employees who were clinicians (physicians, occupational 
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therapists, and physical therapists), researchers, and policy specialists who were familiar 
with mobility devices.  The working group directed a survey of the research literature.  
The review identified only 10 studies that had assessed the benefits of mobility ATDs 
(principally canes, crutches, rollers, and wheelchairs) on users' performance of mobility-
related activities of daily living.  Just one of those studies was a randomised controlled 
trial.  Another was a prospective cohort study, and the rest, with one exception, were 
based on analyses of national survey data.  The working group’s report acknowledges 
that, taken as a whole, the studies are insufficient for guiding decisions about the type of 
mobility ATD, e.g. a quad cane vs. a roller, that is appropriate for individuals with 
particular mobility limitations.  Nevertheless, the group did arrive at a set of guidelines 
regarding the prescription of mobility ATDs and the clinical criteria for their appropriate 
use.  The formal statement by CMS accepting the recommended guidelines acknowledges 
that they were based principally on the working group’s collective expert judgment, 
rather on the available research.    
 Should the AT field expect that expert consensus will continue being achievable 
for future coverage decisions facing Medicare and other payers?  It would be risky to 
assume so.  The breadth of agreement about the value of canes, walkers, rollers, and 
wheelchairs is unlikely to characterize judgments about newer, innovative, often more 
costly technologies with which providers and users have considerably less experience.  
Nor is it likely that payers will continue exempting AT interventions from the evidentiary 
standards they apply to other interventions.  To the contrary, they are likely to place 
greater emphasis on coverage decisions that are based on credible evidence supporting 
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devices’ ostensive benefits, so that those decisions are as transparent and objective as 
possible.   
Presuppositions underlying a strategy for strengthening AT outcomes research  
 The balance of this paper describes a research strategy grounded in mutually 
reinforcing efficacy, effectiveness, and cost-effectiveness studies.  The strategy rests on 
three presuppositions that are discussed initially. 
Prioritizing AT outcome investigations 
 The evaluative strategy being presented is resource intensive, and the AT 
interventions that are candidates for assessment are manifold and numerous, even within 
the mobility domain alone.  Technologies that have only recently emerged from the 
research and development process vie for attention with ones that have been commonly 
available for a considerable time.  Notwithstanding sharp limitations on available 
resources, the outcome studies that are supported should not be limited to devices with 
either one of those histories.   
 Outcome investigations centered on commonly available ATDs may be 
compelling for any number of reasons.  They are especially merited when uncertainty 
prevails about choices among alternative device types, e.g., between powered and manual 
wheelchairs.  Such questions increase in complexity and clinical authenticity when the 
particularities of specific disabling conditions are factored in.  Those particularities are 
exemplified by the erratic course of multiple sclerosis or the uncertain amount of 
recovery following acute-onset conditions such as stroke.  Outcomes involving users’ 
psychological well-being or subjective quality of life may be especially problematic, as 
may outcomes involving individuals other than device users themselves.  Uncertainty 
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exists, for example, about the degree to which supplying individuals with mobility ATDs 
for use in the home increases their independence in the sense of reducing the burden of 
care experienced by cohabitants.  That issue is currently under study by investigators 
affiliated with the Consortium for Assistive Technology Outcomes Research (CATOR) 
[14].  Finally, a standing question exists regarding the ways in which commonly available 
devices fall short of meeting users’ needs. 
 Innovative ATDs emerging from the research and development process merit 
outcomes study as well, especially ones possessing two characteristics.  First, the devices 
should reflect novel design concepts on which a new generation of ATDs may be based.  
Second, they should hold promise for enhancing users’ physical functioning, 
psychological well-being, and device-satisfaction beyond what is being achieved with 
available ATDs.  Studies in the mobility area might assess any number of claims, 
including the following ones:  1) markedly lighter wheelchairs constructed of advanced 
materials result in fewer secondary conditions such as shoulder-joint deterioration;         
2) wheelchairs capable of climbing or descending stairs and curbs are more effective at 
increasing users' social participation; 3) wheelchairs with computerised navigation aids 
do more to increase users' independent mobility; or 4) lower-limb prostheses that are 
micro-processor-controlled allow users to ambulate with greater self-confidence and 
safety from falls.  Third-party payers are likely to resist approving such technologies for 
funding, being skeptical that their ostensibly greater benefits for users are commensurate 
with their typically higher costs.  Well-designed outcomes studies with generally positive 
findings have the potential of neutralizing those reservations, making it more likely that 
the technologies will become available to people who will benefit from their use. 
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Acknowledging the complexity of AT as an intervention      
 Several authors have emphasised that outcome studies must take into account the 
complexity of the interventions being assessed [15,16,].  Approaches that are appropriate 
for evaluating discrete, readily delineated interventions such as pharmacological agents 
have to be considerably adapted to be suitable for assessing interventions comprised of 
multiple, interacting components.  From that standpoint, it is important to recognize the 
actual complexity of AT interventions.  As highlighted in a previously published 
framework for conceptually modelling ATD outcomes [1], the active agent in such 
intervention is not simply the device itself and the services associated with its provision 
and maintenance.  Companion agents, acting as mediating variables, concern devices’ 
operating condition and the extent and manner of their usage.  Devices’ operating 
condition may vary from being “like new” to being inoperable.  Extent of use may vary 
from none at all to use at every opportunity.  Manner of use may differ on several 
dimensions that include whether or not human assistance is involved in the equipment’s 
use, and the degree to which it is being used appropriately, i.e. according to the design 
intent associated with it.  The aggregate of these factors—some related to the device and 
others to its usage—mediates all other outcomes of interest, e.g. the functional benefits 
that users enjoy, their satisfaction with the technology, and its contributions to their 
quality of life. 
The reciprocal relationship between studies’ internal and external validity   
 An ideally designed AT outcomes study is one that strongly supports the 
inferences that 1) the type of ATD and associated services being evaluated were causally 
responsible for the behaviour changes that constituted the outcomes; 2) the study 
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conditions approximated ones under which users customarily acquire their devices, 
thereby enhancing the findings’ “real-world” applicability; and 3) the participants 
represented the diverse populations for which the intervention is relevant.  In short, the 
ideal design is one assuring both the internal and external validity of the findings.  The 
rub is that, practically speaking, those desiderata cannot be realised within the confines of 
a single study.  As methodologists beginning with Cronbach [17] have pointed out, 
features that enhance a study’s internal validity, e.g. restrictively delineated study 
populations, interventions, and outcomes, are precisely ones that attenuate its external 
validity.  Conversely, relaxing those restrictions in order to increase a study’s external 
validity, e.g. by conducting it under ordinary clinical conditions and by encompassing a 
diversity of participants, threatens its internal validity.  
A strategy for establishing important outcomes of AT interventions   
 The tradeoffs between internal and external validity suggest that a single 
outcomes investigation seldom, if ever, is sufficient to provide the evaluative information 
that AT stakeholders need.  Instead, a combination of studies is required, comprised of at 
least one quintessential efficacy study for which internal validity is of utmost concern, 
and one or more quintessential effectiveness studies for which external validity is of 
principal concern.  The number of each kind of study depends on several considerations, 
including the extent to which the resulting findings confirm the value of the AT 
intervention and the need for evidence applicable to specific user populations or service 
settings.           
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 The sequence of efficacy and effectiveness studies will depend on the history of 
the AT intervention in question.  In one case, an ATD representing a new generation of 
technology may just have emerged from the development process.  If so, an efficacy trial 
is especially appropriate in order to confirm its putative benefits under more-or-less ideal 
conditions.  Disappointing findings may suggest the need for developing the technology 
further, while positive results may support plans to market it in its present form.  Initial 
success in the marketplace in turn may stimulate the conduct of effectiveness studies to 
confirm that the technology continues benefiting users who receive it through ordinary 
service channels.         
 In another case, a technology may be like most others that have been vigorously 
marketed without any systematic evidence for their efficacy.  Effectiveness studies, e.g. 
ones conducted by particular clinical programs to assess outcomes for their clients, may 
be the first ones to evaluate a technology.  Generally positive findings are likely to spur 
further interest in it, especially on the part of clinicians and consumers who are oriented 
to evidence-based decision making.  Largely negative findings may result in additional 
effectiveness studies.  If the results continue to be disappointing, an efficacy study may 
be called for to determine if the technology can at least produce the outcomes expected of 
it under more or less ideal conditions.  Few technologies are likely to attract that much 
attention, save for those that represent design concepts to which considerable importance 
is attached.                 
Preparing for efficacy and effectiveness studies     
 The two types of outcome studies require some of the same groundwork.  The 
three preparatory steps discussed below are 1) formulating an intervention theory specific 
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to the AT intervention being evaluated, 2) developing means of documenting intervention 
delivery, and 3) selecting outcome domains and measures. 
Formulating Intervention theory   
Planning efficacy and effectiveness studies entails a large number of reasoned 
choices involving, for example, the populations to sample and the potential confounding 
factors to control.  The rationale for those choices can be made explicit by formulating a 
“small theory”, i.e. one that is specifically applicable to the intervention being 
investigated and to the research context in which it is being administered [18].  A fully 
developed small theory includes specification of: “1) the functional problems on which 
the intervention is intended to impact; 2) characteristics of individuals that make them 
candidates for the intervention; 3) critical features of the intervention that are ostensibly 
responsible for the intended outcomes; 4) elements and contingencies in the causal chain 
connecting provision of the intervention with likely outcomes; and 5) expected changes 
in recipients’ status and in their environment that constitute those outcomes, both near- 
and long-term” [19].  The theory will necessarily be provisional, and it may be 
incomplete, e.g. regarding some of the causal pathways linking features of the AT 
intervention with specific outcomes.  Nevertheless, a study’s small theory can contribute 
importantly to planning it, helping to clarify the hypotheses being tested, and to devising 
the treatment protocol that prescribes how the intervention should be administered.  The 
theory may also be useful in designing statistical procedures such as path analysis that 
depend upon notions of underlying causal relationships.  Finally, the theory offers a 
structure within which to interpret a study’s findings. 
Developing means of documenting intervention delivery     
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 An accurate picture of how interventions are actually administered throughout the 
course of outcome studies is needed for interpreting their results and for possibly 
replicating them.  Study preparations must include, therefore, the design and pilot testing 
of means for monitoring ongoing intervention delivery.  An instrument is currently being 
developed under CATOR auspices for identifying and quantifying salient aspects of 
mobility AT interventions [14].  It features a report that is completed by clinicians 
following each treatment session.  Among the items are ones identifying the clinical 
objectives that were pursued, e.g. client assessment or trial usage of a device, and the 
presence of other individuals such as family members.  All prospectively designed 
outcome studies share a need for aggregated descriptive information of that kind.  The 
data can be especially useful for dealing with the challenge of maintaining treatment 
integrity, i.e. assuring that the intervention is being administered in a manner that 
conforms to the study’s treatment protocol.  That entails continuous scrutiny of the post-
session reports for departures from the protocol, and the initiation of actions to prevent 
future discrepancies.   
Selecting outcome domains and measures  
 The first step in choosing outcome measures is to designate the domains that are 
likely to be impacted by use of the technology.  A provisional taxonomy of AT outcome 
domains has been developed for facilitating those decisions [20].  It encompasses the 
areas of effectivenessthe significance of the technology for the user’s ability to 
function; social significanceits impacts on other people and more generally on society; 
and subjective well-beinghow users appraise and feel about their lives and about the 
particular technology.  The small theory associated with a study should also contribute to 
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selecting outcome domains, and expedient considerations may apply as well.  For 
instance, the permissible timeframe for a study may dictate the choice of outcome 
domains that are expected to be influenced relatively quickly, e.g. in-home mobility, as 
distinguished from domains that require a longer time to exhibit change, e.g. secondary 
conditions such as postural deformities or musculoskeletal problems of the shoulder, 
elbow, or wrist. 
 The culminating step, choosing one or more measures for each selected outcome 
domain, is likely to entail a number of compromises.  Relatively few measures of 
individuals’ functional status are designed in a manner that takes the use of AT into 
account [21].  Measures used in previous AT outcome studies merit consideration, but 
many of them were developed to meet the needs of a particular investigation, without 
much effort being devoted to establishing their psychometric properties [6].   
 A few psychometrically well-developed scales are available for assessing AT 
outcomes.  One is the Quebec User Evaluation of Satisfaction with Assistive Technology 
(QUEST) scale that assesses users’ satisfaction with an ATD and the related services 
[22].  Another is the Psychosocial Impact of Assistive Technology Scale (PIADS) that 
measures users’ psychological well-being [23].  Both instruments’ item-rating formats 
have respondents express their judgments in terms of how they are affected by the 
equipment they are using.  Two other instruments with that format are under 
development.  The Assistive Technology Outcome Measure (ATOM), currently 
undergoing psychometric appraisal, is promising as a means of quantifying the outcomes 
of wheeled mobility AT [24].  Impacts are measured in multiple areas including usage in 
different environments, community participation, functional activity, assistance, comfort, 
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and hassles.  The Assistive Technology Outcomes Profile/M is being developed by 
CATOR collaborators to assess mobility device outcomes in the domains of activity, 
participation, satisfaction, and well-being [14].  Because the instrument is based on the 
application of item response theory and computer adapted testing, only questions that 
retrieve maximum information from device users are administered, thus minimizing 
respondent burden.   
 Efficacy Studies 
 In the context of AT outcomes research, the goal of most efficacy studies is to 
determine unequivocally whether or not particular AT interventions benefit users in their 
daily lives.  Study designers may concede that the device under investigation affords 
users particular performance advantages, e.g., making it less physically demanding to 
move from location to location.  The designers’ intent is to determine if those advantages 
translate into benefits for users and others as the device is used in the home and/or 
community. 
       Efficacy studies have three essential characteristics.  First, they involve a 
comparative format, one in which the intervention of interest is compared with an 
alternative intervention or control condition.  Second, they are based on designs that are 
especially capable of supporting the conclusion that the observed effects of an 
intervention are attributable to it, rather than to extraneous or uncontrolled factors.  Third, 
efficacy studies are typically conducted under relatively restrictive conditions intended to 
maximize impacts of the intervention being assessed.  Each of those characteristics is 
considered below as it may play out in AT outcomes research.    
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 Judicious consideration is required of the comparative intervention or control 
condition to be used in an efficacy study.  That is because the findings of interest concern 
the differences between either of their observed effects and those of the experimental 
intervention, and not just the effects of the experimental intervention alone.  A control 
group in an AT outcomes study that is denied use of the experimental ATD is probably 
not the equivalent of an untreated control group in other areas of study.  Its members are 
unlikely to ignore the functional problems being targeted by the experimental ATD.  
Many control group members can be expected to cope actively with those problems in 
various ways, e.g. by using personal assistants or other types of AT obtained from 
sources unrelated to the study.  The resulting heterogeneity of coping strategies makes it 
difficult to characterize that kind of control condition and to interpret its outcomes.    
 It is feasible to set up a comparison condition involving a different AT 
intervention.  It may entail an ATD that lacks the innovative features of the experimental 
one, but that otherwise addresses similar functional problems.  Implementing such an 
arrangement can be challenging.  On the one hand, a highly particularised technology 
may be selected, e.g. a single ATD having a particular manufacturer and model number.  
Consequently, the comparative findings may not generalize readily beyond it and the 
device being assessed.  On the other hand, a comparison technology may be chosen that 
includes several different devices, their common denominators being the function they 
target and absence of the features that characterize the experimental device.  That 
arrangement, however, may create an interpretive problem of its own, viz., differences 
among the devices may compete with their common denominators as bases for explaining 
the observed outcomes.    
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 The preferred design for an efficacy trial involves the random assignment of 
participants to groups receiving the experimental and comparison interventions [25,26].  
Randomization is key to being able to conclude that differences between the groups’ 
outcomes are attributable to the dissimilarities between the interventions, and not to other 
factors such as preexisting disparities—recognised or not—between the groups being 
compared.  Other means are available for promoting the equivalency of the experimental 
and comparison/control groups.  Participants can be matched on variables that are likely 
to influence the outcomes, independently of the intervention.  Alternatively, statistical 
procedures can be applied retrospectively to correct for between-group differences that 
relate to the outcomes.  However, those maneuvers are only applicable to variables whose 
potential confounding effects are recognised and measured.  Randomization affords the 
enormous advantage of guarding against a host of other variables whose confounding 
effects are real, but unrecognised.  Possible selection bias is thus effectively controlled, 
assuming sufficient sample sizes. 
            Other designs not involving randomization may be considered for efficacy trials.  
Quasi-experimental designs afford a number of possibilities [27].  In one such design, 
experimental and comparison/control groups are formed on other than a randomised 
basis.  For instance, a clinic’s successive clients may be assigned during alternating 3-
month periods to either the experimental or comparison intervention.  Other things being 
equal, stronger internal validity is associated with that kind of design than with ones 
based solely on before-after comparisons of an intervention’s effects or on case studies.  
Still, quasi-experimental designs lack the strength of randomised designs for realizing the 
primary purpose of efficacy studiesassuring that observed differences between the 
 17
effects of experimental and comparison/control conditions are due to the dissimilarities 
between those conditions, and not to other factors.    
 Randomization alone does not assure a study’s internal validity.  Other threats 
may exist including persisting initial differences between the groups being compared, 
differential dropout rates, noncompliance with intervention protocols, and failures to 
maintain differences between the experimental and comparison conditions.  Bias also 
may result from an inability to blind participants and investigators to the interventions 
being administered.  That seems to be an unavoidable limitation of AT outcome studies, 
as it is for most rehabilitation-oriented outcome studies.   
 Because the chief concern of efficacy studies is to detect any treatment effects, 
researchers try to eliminate or hold constant factors that may obscure them.  The 
conditions of administering the experimental and comparison/control conditions are 
ideally under tight control, and as such, may depart from usual practice conditions.  For 
example, both the experimental and comparison interventions are likely to be manualised 
to assure they are administered in a standardised fashion.  Especially well qualified and 
trained individuals are used to administer the interventions, and special efforts are made 
to maximize participants’ adherence to the intervention regimens.   
Effectiveness Studies  
 Outcome studies are needed having interventions that are adaptable to usual 
clinical services, findings that have known relevance to those services, and study samples 
that represent many of the populations whose members are candidates for such services.  
Effectiveness studies attempt to fulfill those needs by evaluating interventions under 
conditions that typify usual service provision [28].  Such studies are central to a 
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translational research strategy aimed at encouraging the use of AT interventions of 
demonstrated value.  
Effectiveness studies embody the realities of usual clinical practice in several 
ways.  Interventions are typically delivered by line clinicians who do not have the 
intensive, specialised training of their counterparts in efficacy trials.  The guidelines for 
administering interventions do not regiment practices to the degree that occurs in efficacy 
studies, and greater variability is often permitted in the timing or duration of participant 
contacts. 
Effectiveness studies frequently have the goal of documenting an intervention’s 
benefits for populations that were excluded from a preceding efficacy study.  Any 
number of population parameters may be explored, including ones that pertain to 
individuals’ impairments, co-existing medical conditions, treatment histories, or living 
conditions. 
Effectiveness studies may encompass a variety of designs and still fulfill their 
essential purposes.  Experimental and comparison interventions may be administered to 
different cohorts, or they may be administered in a controlled order to the same 
individuals.  Alternatively, changes may be documented in a single group of participants 
before and after the experimental intervention is administered.  Effectiveness can be 
evaluated in follow-up studies conducted by particular service programmes, or rest on the 
study of community-based populations that are the subjects of survey research.  
Hybridizing effectiveness and efficacy designs   
Proposals have been made to mitigate the limitations of efficacy trials by building 
features of effectiveness studies into them [29,30].  One way of doing that is to add an 
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independent variable that normally is limited to effectiveness studies.  For instance, a 
variable might be added to an efficacy study that concerns the exactness with which the 
intervention is delivered.  The desired practices might be administered in a highly 
regimented manner under one condition.  In another, practitioners would be steeped in 
the intervention’s underlying principles, but its implementation would be left to their 
discretion.  The transferability of the intervention to clinical practice presumably would 
be enhanced if it proved to be as effective under the latter condition as under the former 
one.  Note, however, that this augmented study design would require a substantial 
increase in the number of participants.  Indeed, the enlarged scale and correspondingly 
higher costs of hybrid studies are their foremost liabilities.  That increased expenditure is 
difficult to justify before the efficacy of an experimental intervention has even been 
established.  
Cost-effectiveness Studies 
 From a cost-containment perspective, AT is vulnerable to being tarred by the 
same brush that has been applied to health technology generally, namely, the accusation 
that it is a driver of increasing healthcare costs.  A meaningful response to that concern 
requires that knowledge about the effectiveness of AT interventions be complemented by 
information about their costs.  That is an issue of cost-effectiveness, viz., the incremental 
difference in cost that is associated with an incremental difference in outcome, comparing 
one AT intervention with another.  Here, “incremental” refers to the difference between 
the cost (or outcome) of the intervention and the cost (or outcome) of an alternative one.   
 Cost-effectiveness studies pose their own distinctive demands.  Their outcomes 
frequently take the form of health utilities, i.e. systematically determined preferences for 
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particular health states [31].  Diverse outcomes can be integrated into a single score, thus 
facilitating comparisons among interventions.  Considerable controversy exists, however, 
regarding the extent to which the utilities determined for one population (e.g. individuals 
with chronically disabling conditions) apply to other populations (e.g. individuals without 
such conditions) [32]. 
 Data pertaining to costs are of little value unless they are captured 
comprehensively and in a state-of-the-art manner [33].  For AT interventions, the costs of 
devices are relevant, as are expenditures for services associated with their provision and 
maintenance.  Included in the latter two categories are costs related to assessing candidate 
users, selecting, and ordering devices, adapting them to users’ needs, training individuals 
in their use, and keeping devices in operating condition.  Expertise in health economics is 
needed to assure that such costs are quantified appropriately in AT outcomes studies.  
Informed judgment is required at numerous junctures, e.g., critiquing stated prices in 
terms of how well they represent actual costs, suggesting appropriate methods for 
capturing overhead costs, and seeing to it that all of the parties who are incurring costs 
are represented.  Among those parties are device users, their family members, AT 
providers, third-party payers, employers, the government, and society as a whole.  
Achieving consensus on a comprehensive categorization of the resources consumed by 
AT interventions will constitute an important first step in achieving the standardization of 
cost measures called for by Harris and Sprigle [34].   
   Cost-effectiveness studies require a groundwork of preceding studies in order to 
be meaningful.  Apropos of being effectiveness studies, their underlying design is 
typically one that stresses the external generalisability of the findings, i.e. their 
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applicability to the world of ordinary service provision.  In short, the internal validity of 
their findings is often not their strong suite.  That underscores the importance of 
outcomes findings being available from companion studies in which internal validity was 
a principal concern.   
Some Ways Forward 
 Two steps are discussed below for increasing the amount and quality of evaluative 
knowledge that users, clinicians, and payers have about AT interventions.  One is 
concerned with strengthening opportunities for collaborative AT outcomes research, the 
other, with increasing research funding. 
Infrastructure for facilitating collaboration  
An AT outcomes investigation requires a team of principals who bring different 
backgrounds, capabilities, and resources to the endeavor.  Skills in designing and 
implementing outcome studies and in analyzing the resulting data may be supplied by 
some individuals, while others contribute clinical expertise in providing AT services and 
mobilizing the cooperation of needed services settings.  Projects devoted to evaluating 
outcomes of a new technology may also include individuals who participated in its 
development.  Assembling and sustaining such teams can be demanding, because their 
members often represent distinct institutional cultures and because they may have had 
little or no history of working together.   
 Outcomes research networks, standing consortia of academic and clinical settings 
that collaborate in conducting efficacy, effectiveness, and cost-effectiveness studies in 
defined areas, are a way of fostering the required teams of researchers.  The Traumatic 
Brain Injury Clinical Trials Network funded by the National Center for Medical 
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Rehabilitation Research (NCMRR) nicely exemplifies this kind of cooperative endeavor 
[35].  The formation of AT outcomes research networks could serve an important 
bridging function among AT researchers, clinicians, and developers.  The networks might 
be distinguished by the type of AT on which they focus (e.g. for mobility or for 
augmentative and alternative communication), impairment groups (e.g. stroke or spinal 
cord injury), age groups (e.g. children or elderly individuals), or by a combination of such 
factors.  The networks would share the aims of shortening the start-up times of AT 
outcomes studies, ensuring that a broad spectrum of expertise is drawn on in planning 
and conducting those studies, and of expediting the recruitment of participants from 
relevant study populations.  They could pursue those aims by identifying and 
disseminating information about best practices for conducting AT outcome studies; 
publicizing training opportunities; and by maintaining two kinds of registriesa technical 
assistance registry profiling individuals with skills in developing study protocols and 
conducting data analyses, and a facilities registry profiling clinical sites that serve defined 
AT user populations and that are willing to consider collaboration in outcome studies.  
The networks might be fostered initially by an organisation such as the Rehabilitation 
Engineering and Assistive Technology Society of North America (RESNA) [36] or the 
American Congress of Rehabilitation Medicine (ACRM) [37], and subsequently 
encompass collaboration with European organisations such as the Association for the 
Advancement of Assistive Technology in Europe (AAATE) [38].  The evolved, 
externally funded versions of the networks might be able to support the conduct of pilot 
studies that are selected on a competitive basis.  The successful projects might then 
mature into full-scale investigations funded by other means. 
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Funding 
 Research projects devoted to evaluating the efficacy, effectiveness, or cost-
effectiveness of AT interventions are entirely legitimate candidates for funding by both 
the National Institute on Disability and Rehabilitation Research (NIDRR) and by 
NCMRR, the federal agencies supporting the preponderance of rehabilitation-related 
research in the USA.  The NIDRR-funded Rehabilitation Engineering Research Centers 
(RERC) programme is an especially appropriate host for such projects in view of its 
commitment to fostering research and development that advances AT in numerous areas, 
including mobility [39].  However, judging from abstracts describing the centres’ work, 
outcome studies that evaluate the value of those advances do not figure prominently in 
their research agendas [40].  Nor has NIDRR given much visibility to such research in 
either its recently updated long-range plan [39] or its announcements of funding 
competitions for the extant RERCs.  This neglect may flow from the questionable view 
that the centres’ commitments to making AT advances have been fully discharged once 
prototypes of innovative devices are available and are handed off to manufacturers for 
commercialization.    
 Other especially relevant funding mechanisms are the Small Business Innovation 
Research (SBIR) and Small Business Technology Transfer (STTR) programmes 
administered by both NIDRR and NCMRR.  Both agencies are required by federal law to 
set aside a specified portion of their annual budgets to fund those programmes.  The 
grants support small businesses that are pursuing research or development efforts that 
have the potentiality of being commercialised and of benefiting the public.  Collaboration 
between individuals affiliated with the small companies and academically affiliated 
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researchers is a hallmark of both programmes.  Assistive technology research and 
development is well represented among the SBIR and STTR projects being supported 
currently by both NIDRR [41] and NCMRR [42].  However, those projects do not 
frequently incorporate either efficacy or effectiveness studies.  That is unfortunate in 
view of the fact that SBIR and STTR applications have higher success rates than several 
other kinds of applications.  Both agencies should do more to encourage applicants to 
make outcome studies an integral part of the AT development process.  That would 
doubtlessly stimulate that research, and at the same time, help fulfill the objectives of the 
SBIR and STTR programmes.       
 Additional funding sources can contribute significantly to meeting the costs of AT 
outcome investigations.  The manufacturers of the devices being evaluated can contribute 
by making them available at no cost to the research efforts.  Payers for AT services might 
participate as well.  Medicare, for example, now pays all routine costs of care for 
individuals enrolled in clinical trials supported by the National Institutes of Health (NIH).  
The possibility should be explored of extending that policy to covering services 
associated with AT outcome studies being funded by NCMRR or other NIH components. 
Summary and Conclusions 
 Assistive technology devices are potentially of vital importance for maintaining 
the functioning, independence, and quality of life of people who are challenged by 
mobility-related impairments.  The demand for those devices is sure to grow in view of 
the aging of the population and the dramatic increase in the use of AT by elderly people 
with disabilities [43.44].  A major industry exists to meet that demand.  It supplies a wide 
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array of equipment options, some that have been long available and others that are based 
on relatively recent advances in the engineering sciences.   
 Users, clinicians, and payers all have a stake in having available a solid 
evidentiary base for guiding equipment decisions.  Their need will become even greater 
as pressure continues mounting to contain the costs of health-related products and 
services, and as the rate of major advances accelerates.  Discussion is needed about the 
investigative strategies that are best suited to obtain the necessary evidence.  This paper 
has focussed on a strategy involving mutually reinforcing studies of the efficacy, 
effectiveness, and cost-effectiveness of AT interventions.  Its realization will require 
vigorous effort by members of the field to marshal the requisite investigative 
resources─financial, human, and institutional.  That cannot happen until more of a 
consensus is reached about the field’s evaluative research needs and about the most 
promising avenues for fulfilling them.  A purpose of this paper has been to energize that 
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